United Kingdom Molecular Diagnostics Market By Component (Instruments, Reagents, Software, Services), By Technology (PCR, DNA Sequencing, Hybridization, Microarray, INAAT, Others), By Application (Oncology, Infectious Disease Testing, Genetic Testing, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Molecular Diagnostics Market By Component (Instruments, Reagents, Software, Services), By Technology (PCR, DNA Sequencing, Hybridization, Microarray, INAAT, Others), By Application (Oncology, Infectious Disease Testing, Genetic Testing, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
United Kingdom Molecular Diagnostics
Growing Prevalence of Chronic Diseases
With the rising prevalence of chronic disease, the demand for effective molecular diagnostics in the United Kingdom has witnessed a notable surge. Chronic diseases have become a leading cause of morbidity and mortality worldwide, and the United Kingdom is no exception. Factors such as an aging population, sedentary lifestyles, unhealthy dietary habits, and environmental factors contribute to the increasing prevalence of chronic conditions. According to the National Health Service (NHS), cancer and cardiovascular diseases remain the two most common causes of death in the United Kingdom. Additionally, the emergence of drug-resistant infections and the rising incidence of genetic disorders have further amplified the need for accurate and personalized diagnostics. This is expected to propel the growth of the United Kingdom Molecular Diagnostics Market. The United Kingdom molecular diagnostics market is witnessing robust growth due to the increasing demand for advanced diagnostic techniques. Technological advancements, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray technologies, have revolutionized the field. These technologies allow for high-throughput analysis, improved sensitivity, and specificity, making them ideal for early disease detection and monitoring, thus augmenting the growth of the United Kingdom Molecular Diagnostics Market.
Technological Advancements Propel United Kingdom Molecular Diagnostics Market
One of the key technological advancements driving the United Kingdom's molecular diagnostics market is the advent of next-generation sequencing (NGS). NGS has revolutionized genomic research and diagnostics by enabling rapid and cost-effective sequencing of DNA and RNA. This technology has significantly expanded the understanding of genetic variations and their role in diseases, allowing for more accurate diagnoses and personalized treatment plans. NGS has found applications in various areas, including oncology, infectious diseases, and genetic disorders, and has become an integral part of molecular diagnostic laboratories across the country.
Another significant technological advancement is the development of innovative molecular testing platforms. These platforms combine automation, miniaturization, and high-throughput capabilities, allowing for faster and more efficient testing. For example, polymerase chain reaction (PCR) machines have evolved from conventional thermal cyclers to real-time PCR systems, which enable the quantification of target molecules in real-time. These advanced platforms offer improved sensitivity, specificity, and turnaround time, making them invaluable tools for diagnosing infectious diseases, monitoring treatment responses, and detecting genetic mutations.
The United Kingdom has also embraced digital pathology, which involves the digitization and analysis of histopathology slides. Digital pathology systems enable pathologists to access and review high-resolution digital images of tissue samples remotely, facilitating collaboration, second opinions, and archival purposes. This technology has the potential to improve diagnostic accuracy, reduce turnaround time, and enhance patient care. Additionally, the integration of artificial intelligence (AI) algorithms with digital pathology platforms holds great promise in automating image analysis and aiding pathologists in detecting subtle patterns or abnormalities that may be missed by the human eye.
According to the Office for National Statistics, in 2021, the total current healthcare expenditure increased by 7.1% in real terms compared to 10.0% in 2020, after accounting for the effects of inflation on the economy as a whole
Increase in Demand for Genetic Testing Drives United Kingdom Molecular Diagnostics Market
In recent years, the United Kingdom has witnessed a significant increase in demand for genetic testing, contributing to the rapid growth of the molecular diagnostics market. This surge in demand can be attributed to several factors, including advancements in technology, rising awareness of genetic diseases, and a shift towards personalized medicine. One of the key drivers of increased demand for genetic testing in the United Kingdom is the rapid advancements in technology. The field of molecular diagnostics has witnessed remarkable progress in recent years, particularly in sequencing technologies such as next-generation sequencing (NGS). NGS has revolutionized genetic testing by enabling the simultaneous analysis of multiple genes and providing comprehensive insights into an individual's genetic makeup. The declining costs of sequencing technologies have made genetic testing more accessible and affordable, thus encouraging its adoption among healthcare professionals and individuals seeking to understand their genetic predispositions, leading to the growth of the United Kingdom Molecular Diagnostics Market.
Recent Developments
- In July 2022, Siemens Healthineers unveiled The Atellica CI 1900 Analyzer at the American Association for Clinical Chemistry 2022. It is a clinical chemistry and immunoassay testing system, serving as a lower volume variant of Siemens Healthineers' currently marketed Atellica clinical chemistry and immunoassay testing solution. The system has the capacity to perform over 25,000 immunoassay tests and over 250,000 clinical chemistry tests annually. According to Siemens Healthineers, the new analyzer can be used as a stand-alone system in hub-and-spoke configurations connected to integrated delivery networks.
Mergers & Acquisitions
- In March 2020, Thermo Fisher Scientific and Johnson & Johnson's Janssen Biotech announced a collaborative effort to co-develop a companion diagnostic (CDx) in the field of oncology. As part of this agreement, Thermo Fisher and Janssen's R&D scientists will collaborate to validate biomarkers for use with Thermo Fisher's Oncomine DX target test. The aim is to identify variant-positive patients for enrollment into clinical trials focusing on non-small cell lung cancer (NSCLC).
- In March 2023, Mylab Discovery Solutions and DnaNudge announced a strategic alliance to develop advanced molecular diagnostic tools for the early detection of diabetic foot ulcers and other serious illnesses.
Market Segmentation
The United Kingdom Molecular Diagnostics Market is categorized into different segments, including Component, Technology, Application, End User, Region and Company. In terms of Component, it is divided into Instruments, Reagents, Software, and Services. The Technology segment comprises PCR, DNA Sequencing, Hybridization, Microarray, INAAT, and others. The Application segment includes Oncology, Infectious Disease Testing, Genetic Testing, and others. End User categories are Hospitals & Clinics, Diagnostic Laboratories, and others. The market is further segmented by region, including Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
Johnson & Johnson, Abbott Laboratories Ltd., Siemens Healthineers AG, Hologic Inc., Qiagen N.V., Becton, Dickinson and Company Ltd, bioMérieux SA, Agilent Technologies Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd are some of the key players in the United Kingdom Molecular Diagnostics market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company shares, competitive landscape, growth factors, and trends |
| Segments covered | Component Technology Application End User Region |
| Country scope | Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands |
| Key companies profiled | Johnson & Johnson, Abbott Laboratories Ltd., Siemens Healthineers AG, Hologic Inc., Qiagen N.V., Becton, Dickinson and Company Ltd, bioMérieux SA, Agilent Technologies Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy